Table 3.
Association between oxidative balance score and colorectal cancer and its subsites stratified by sex.
| Continue | Quantile | P for trend | ||||
|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | |||
| CRC in male, HR (95% CI), P-value | ||||||
| Model 1 | 0.968(0.958~0.978), <0.001 | Ref. | 0.789(0.682~0.913), 0.001 | 0.726(0.634~0.832), <0.001 | 0.665(0.579~0.764), <0.001 | <0.001 |
| Model 2 | 0.967(0.956~0.978), <0.001 | Ref. | 0.794(0.683~0.924), 0.003 | 0.720(0.624~0.831), <0.001 | 0.662(0.570~0.769), <0.001 | <0.001 |
| Model 3 | 0.967(0.956~0.977), <0.001 | Ref. | 0.793(0.682~0.922), 0.003 | 0.718(0.622~0.829), <0.001 | 0.659(0.568~0.766), <0.001 | <0.001 |
| Proximal colon cancer in male, HR (95% CI), P-value | ||||||
| Model 1 | 0.980(0.961~0.999), 0.040 | Ref. | 1.122(0.851~1.481), 0.414 | 0.885(0.676~1.159), 0.376 | 0.802(0.609~1.055), 0.114 | 0.038 |
| Model 2 | 0.975(0.955~0.996), 0.020 | Ref. | 1.119(0.842~1.488), 0.439 | 0.847(0.638~1.124), 0.249 | 0.761(0.567~1.022), 0.070 | 0.020 |
| Model 3 | 0.974(0.954~0.995), 0.016 | Ref. | 1.114(0.837~1.481), 0.459 | 0.841(0.634~1.116), 0.231 | 0.752(0.560~1.011), 0.059 | 0.016 |
| Distal colon cancer in male, HR (95% CI), P-value | ||||||
| Model 1 | 0.949(0.931~0.967), <0.001 | Ref. | 0.559(0.425~0.736), <0.001 | 0.631(0.497~0.800), <0.001 | 0.512(0.398~0.658), <0.001 | <0.001 |
| Model 2 | 0.947(0.928~0.966), <0.001 | Ref. | 0.560(0.423~0.741), <0.001 | 0.621(0.484~0.796), <0.001 | 0.507(0.387~0.664), <0.001 | <0.001 |
| Model 3 | 0.947(0.928~0.966), <0.001 | Ref. | 0.560(0.422~0.741), <0.001 | 0.620(0.483~0.796), <0.001 | 0.506(0.387~0.663), <0.001 | <0.001 |
| Rectal cancer in male, HR (95% CI), P-value | ||||||
| Model 1 | 0.976(0.958~0.994), 0.008 | Ref. | 0.786(0.603~1.024), 0.075 | 0.759(0.595~0.969), 0.027 | 0.759(0.595~0.967), 0.026 | 0.028 |
| Model 2 | 0.978(0.959~0.998), 0.029 | Ref. | 0.793(0.602~1.044), 0.099 | 0.774(0.599~1.002), 0.051 | 0.790(0.607~1.028), 0.079 | 0.085 |
| Model 3 | 0.978(0.959~0.997), 0.026 | Ref. | 0.791(0.601~1.042), 0.096 | 0.772(0.597~0.999), 0.049 | 0.786(0.604~1.023), 0.074 | 0.079 |
| CRC in female, HR (95% CI), P-value | ||||||
| Model 1 | 1.000(0.988~1.012), 0.994 | Ref. | 0.863(0.709~1.051), 0.143 | 0.965(0.810~1.150), 0.688 | 0.981(0.828~1.163), 0.824 | 0.798 |
| Model 2 | 0.995(0.983~1.008), 0.481 | Ref. | 0.877(0.716~1.073), 0.202 | 0.951(0.792~1.143), 0.594 | 0.940(0.784~1.128), 0.507 | 0.755 |
| Model 3 | 0.995(0.983~1.008), 0.477 | Ref. | 0.876(0.716~1.073), 0.202 | 0.951(0.792~1.142), 0.593 | 0.940(0.783~1.128), 0.505 | 0.752 |
| Proximal colon cancer in female, HR (95% CI), P-value | ||||||
| Model 1 | 0.995(0.974~1.015), 0.605 | Ref. | 0.761(0.545~1.062), 0.108 | 0.780(0.577~1.052), 0.104 | 0.861(0.648~1.144), 0.301 | 0.436 |
| Model 2 | 0.994(0.972~1.017), 0.602 | Ref. | 0.772(0.543~1.096), 0.148 | 0.795(0.578~1.092), 0.157 | 0.869(0.639~1.183), 0.373 | 0.521 |
| Model 3 | 0.994(0.972~1.016), 0.592 | Ref. | 0.771(0.543~1.096), 0.147 | 0.794(0.578~1.092), 0.156 | 0.868(0.637~1.181), 0.366 | 0.513 |
| Distal colon cancer in female, HR (95% CI), P-value | ||||||
| Model 1 | 1.014(0.992~1.037), 0.215 | Ref. | 0.961(0.658~1.403), 0.837 | 1.212(0.871~1.687), 0.255 | 1.230(0.891~1.699), 0.209 | 0.105 |
| Model 2 | 1.007(0.983~1.031), 0.585 | Ref. | 0.941(0.640~1.382), 0.755 | 1.126(0.799~1.587), 0.498 | 1.151(0.819~1.619), 0.418 | 0.276 |
| Model 3 | 1.006(0.983~1.031), 0.597 | Ref. | 0.940(0.640~1.381), 0.752 | 1.125(0.798~1.585), 0.502 | 1.149(0.817~1.615), 0.426 | 0.282 |
| Rectal cancer in female, HR (95% CI), P-value | ||||||
| Model 1 | 0.976(0.952~1.000), 0.048 | Ref. | 0.996(0.692~1.435), 0.985 | 0.840(0.594~1.189), 0.325 | 0.753(0.533~1.064), 0.107 | 0.064 |
| Model 2 | 0.970(0.945~0.995), 0.019 | Ref. | 1.010(0.698~1.460), 0.959 | 0.796(0.556~1.140), 0.212 | 0.691(0.479~0.996), 0.048 | 0.022 |
| Model 3 | 0.970(0.945~0.995), 0.019 | Ref. | 1.010(0.698~1.460), 0.958 | 0.796(0.556~1.140), 0.213 | 0.692(0.480~0.997), 0.048 | 0.022 |
The hazard ratio value of Q2-Q4 is based on the Q1 group as the reference. Model 1 was adjusted for age, race, educational attainment, and Townsend deprivation index. Model 2, building upon Model 1, adjusted for dietary energy intake; Model 3: In addition to Model 2, adjusted for plasma CRP concentration and NSAIDs medication usage. CRC, Colorectal Cancer; HR, Hazard Ratio. CI, confidence interval.